Scoping review protocol documenting cancer outcomes and inequalities for adults living with intellectual and/or developmental disabilities

Morgan Stirling,¹ Janice Linton,¹ Hélène Ouellette-Kuntz,² Shahin Shooshtari,¹ Julie Hallet,³ Christine Kelly,¹ David Dawe,⁴,⁵ Mark Kristjanson,⁶,⁷ Kathleen Decker,¹,⁸ Alyson Mahar¹

INTRODUCTION
There is greater attention and focus on the burden of cancer among individuals with intellectual and developmental disabilities (IDD). IDD, including Down syndrome, cerebral palsy and autism spectrum disorder, are life-long disorders originating before the age of 18 and affect 1%–3% of the population. IDD diagnoses range from mild to profound impairment with features such as diminished communication, difficulty processing information and problem solving, as well as challenges with activities of daily living.¹² Significant improvements in life expectancy,¹³ the recognition that cancer is a leading cause of death in persons with IDD³⁶ and the possibility that significant limitations in intellectual functioning may make it challenging for persons with IDD to access and navigate a cancer setting¹² are influencing this shift in focus.

Disparities in cancer outcomes persist within universal healthcare systems across the cancer control spectrum, from prevention to survivorship and end-of-life care. Many of the factors...
influencing these disparities are not connected to the cancer itself, but to a person’s social and economic context that shape their ability to access cancer care. Groups most vulnerable to these disparities are ones that experience discrimination and underlying levels of economic, social and geographic disadvantage.37 Cancer risk factors, screening rates, stage at diagnosis, receipt of guideline-recommended treatment, symptom management and cancer mortality vary by age, sex, immigration status, sexual orientation, socioeconomic position, geographic location, rurality and in indigenous populations.9–22 International, national and local cancer agencies have directed efforts to addressing barriers that lead to poorer outcomes and experiences for vulnerable populations.25–27 To make clinical care and delivery of support services more responsive to the needs of the vulnerable groups, there is an imperative to improve understanding of disparities within the cancer system. While this is an emerging area of research, there has been a lack of focus on the needs of adults with IDD, leaving many unanswered questions.28 29

Adults with IDD may be at greater risk of worse outcomes along the cancer continuum for a number of reasons.29 30 Potential pathways are related to features of IDD, that is, cognitive deficits and difficulties with communication and are influenced by the social determinants of health that shape one’s economic and material reality.31 In particular, determinants such as provider bias and ableism; lower levels of employment, education and social support; lack of access to suitable transportation; a lack of provider knowledge and organisation of the health system that hinders access to services have been suggested as mechanisms leading to poorer outcomes.32–37 Existing literature reviews focusing on cancer and IDD to inform provider and system-level interventions are narrative in nature,28 29 38 analyse a handful of studies on a particular cancer type38 39 or do not highlight modifiable barriers to improve cancer care, limiting actionable content.28 29 30 This review seeks to address this gap and provide an overview of the literature on cancer outcomes among adults with IDD and the factors that influence them over the cancer continuum, from risk and prevention to end-of-life/survivorship.

The primary objectives of this scoping review are to systematically map and examine the evidence base comparing cancer outcomes for adults with IDD to those without, to explore the literature describing cancer care experiences for adults with IDD. It will focus primarily on cancer incidence, screening, staging, treatment and prognosis. Our goals are to direct future research efforts by identifying literature gaps and limitations, and highlight relevant social determinants of health influence cancer outcomes for individuals with IDD. It is our hope that this review will expand the wider body of research examining cancer disparities for vulnerable populations.

**METHODS AND ANALYSIS**

A scoping methodology approach will be used to explore the literature describing cancer outcomes for individuals with IDD. Scoping reviews can examine broad questions that aim to describe research activity in an area and its evidence base.40–42 We will follow the expanded Arksey and O’Malley (2005) framework for scoping reviews.40–42 We will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for reporting scoping reviews: PRISMA-Scoping Reviews checklist.43

**Identifying the research question**

The scoping review will answer the questions:

1. What are the effects of living with an IDD on adult cancer risk, screening, stage at diagnosis, treatment and survival relative to those without IDD?
2. What factors related to features of IDD may contribute to differences in cancer care experiences and outcomes for individuals with IDD compared with those without?
3. What social determinants of health may contribute to differences in cancer care experiences and outcomes for individuals with IDD compared with those without?

The research team developed these questions and initial protocol in an iterative process and will revise the protocol as needed throughout the review process.

**Search strategy and information sources**

The primary search strategy was developed for Medline by the research team in collaboration with a health sciences librarian (JL). We will execute a similar search in Embase, Cochrane, CINAHL, Scopus and PsycINFO. The search will employ the following Medical Subject Headings (MeSH) headings for IDD and cancer, respectively, and will be linked with Boolean operator AND within a category and using the Boolean operator AND between IDD and cancer:

- IDD: [exp intellectual disability/], [exp Developmental Disabilities/]; [exp Child Development Disorders, Pervasive/].
- Cancer: exp [neoplasms/].

Preliminary searches in Medline and Embase identified 749 and 1916 potential citations, respectively. We have elected to complete a sensitive strategy given the lack of specificity in cancer-related MeSH headings for our research objectives. A copy of the search strategy has been included as an online supplementary file. We will restrict the study to those articles published in 2000 or later to best approximate the risk of cancer and cancer-related outcomes in adults living with IDD currently, given changes in IDD definitions and increased life expectancy over time.4 We will also review reference lists of relevant review articles and perform a cited reference search of included studies.

**Study selection**

Study selection will follow two stages. The first will be an initial review of titles and abstracts by two reviewers. The initial review will be done independently, with reviewers discussing results once screening is complete. Resolving disagreement will be attempted first by the two reviewers,


other relevant timepoints, palliation, follow-up therapy, radiation and surgery), survival from diagnosis or screening rates, stage at diagnosis, treatment (eg, chemotherapy), information will be noted. Cancer incidence, prevalence, with IDD and is their caregiver or healthcare provider, this size. For studies where the study population is not adults
registry), study time frame, study location and sample sources of information (eg, hospital records and cancer study, cancers included (eg, lung, breast and melanoma), along the cancer continuum is explored in the milestones along the cancer continuum, including risk, screening, diagnosis, treatment, end-of-life/survivorship and survival. Studies where multiple health outcomes are reported, but cancer outcomes must be reported separately. Biological, anatomical and/or social characteristics contributing to cancer outcomes or experiences for individuals with IDD.

Table 1 outlines the inclusion/exclusion criteria following the population, concept and context categories for scoping reviews. Due to expertise within the team, we will include studies in both English and French.

<table>
<thead>
<tr>
<th>Population</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults (age ≥18) with an intellectual and/or developmental disability ± a comparison group of adults with cancer and without an IDD.</td>
<td>Cancer outcomes for adults are not reported separately from children. IDD definition is not consistent with current approaches or cannot be confirmed.</td>
</tr>
<tr>
<td>Concept</td>
<td></td>
</tr>
<tr>
<td>Any cancer diagnosis occurring age ≥18</td>
<td>Studies on health of adults with IDD where no cancer-related outcomes are reported/cancer-related outcomes not reported separately. Primary focus is the relationship between cancer genes/pathways and IDD.</td>
</tr>
<tr>
<td>Studies reporting cancer outcomes or experiences occurring along the continuum, including risk, screening, diagnosis, treatment, end-of-life/survivorship and survival. Studies where multiple health outcomes are reported, but cancer outcomes must be reported separately. Biological, anatomical and/or social characteristics contributing to cancer outcomes or experiences for individuals with IDD.</td>
<td></td>
</tr>
<tr>
<td>Context</td>
<td></td>
</tr>
<tr>
<td>English and French</td>
<td></td>
</tr>
<tr>
<td>Original research articles (Random Controlled Trials, cohort study, case–control and cross-sectional) Qualitative or quantitative Papers published after 2000.</td>
<td>Opinion papers Editorials Conference abstracts Case reports Systematic reviews, meta-analyses, network meta-analyses, narrative reviews, critical reviews and qualitative reviews theses/dissertations.</td>
</tr>
</tbody>
</table>

IDD, intellectual and developmental disabilities.

but if necessary a third member of the research team will be consulted to reach consensus. Once the initial decision on which articles to include, we will begin the second stage of conducting a full-text review. Two reviewers will assess the articles to determine whether it meets the inclusion criteria. Those articles where there is uncertainty will be reviewed by a third member of the team to determine its eligibility. Table 1 outlines the inclusion/exclusion criteria following the population, concept and context categories for scoping reviews. Due to expertise within the team, we will include studies in both English and French.

Charting the data
A data chart will be developed in consultation with the research team. This chart will facilitate the collection and sorting of information from selected studies. Key areas that will be included in this chart will include: description of study population (eg, age, sex, socioeconomic status and comorbidity), definition of IDD, IDD diagnosis, context of IDD care (eg, institution and community), which milestone along the cancer continuum is explored in the study, cancers included (eg, lung, breast and melanoma), sources of information (eg, hospital records and cancer registry), study time frame, study location and sample size. For studies where the study population is not adults with IDD and is their caregiver or healthcare provider, this information will be noted. Cancer incidence, prevalence, screening rates, stage at diagnosis, treatment (eg, chemotherapy, radiation and surgery), survival from diagnosis or other relevant timepoints, palliation, follow-up care during remission, recurrence rates and quality of life measures will be quantified and measures of comparison to the general cancer population extracted where possible. Major themes from qualitative studies will be extracted and summarised across studies. Where possible we will summarise quantitative and qualitative data within and across IDD diagnoses as well as within and across countries. The data chart will be piloted by two reviewers, with differences in charting to be resolved by a third member of the research team. After initial pilot, results will be shared with the research team to determine whether the data chart satisfactorily captures information to respond to research questions. Revisions will be incorporated if determined necessary.

Collating, summarising and reporting the results
Results will be summarised both quantitatively and qualitatively to provide a description of collected data. Descriptive statistics indicating frequencies and central measures of tendency will be used to report the number of studies reporting outcomes or care experiences at each stage of the cancer continuum, as well as the type of contributing characteristic(s) such as biological, social or economic factors will also be reported. The descriptive statistics will be reported in tables. A narrative synthesis of the findings will also be reported.

Consultation
We will engage with relevant stakeholders, including individuals within the IDD community such as individuals with IDD, their family members and service providers, as...
well as community organisations, to determine suitable approaches for dissemination and additional knowledge translation activities.

**Patient and public involvement**

Patients and the public were not involved in the development of this protocol.

**CONCLUSION**

This protocol outlines a rigorous method to systematically search and map the literature on cancer outcomes and care for individuals with IDD. To the best of the research team’s knowledge, this is the first review that attempts to explore this area in any great detail. Significantly, this scoping review has the potential to highlight gaps and limitations in the existing body of research, and as such can provide direction for future inquiry.

**Author affiliations**

1. Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
2. Department of Public Health Sciences, Queen’s University, Kingston, Ontario, Canada
3. Department of Surgery, University of Toronto, Toronto, Ontario, Canada
4. Internal Medicine, University of Manitoba College of Medicine, Winnipeg, Manitoba, Canada
5. Hematology and Medical Oncology, CancerCare Manitoba, Winnipeg, Manitoba, Canada
6. Community Oncology Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada
7. Department of Family Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
8. Department of Public Health Sciences, Queen’s University, Kingston, Ontario, Canada
9. Community Oncology Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada
10. Medical Oncology, University of Manitoba, Winnipeg, Manitoba, Canada
11. Community Oncology Program, CancerCare Manitoba, Winnipeg, Manitoba, Canada

**Contributors**

MS and AM conceived of and developed the protocol. JL, AM and MS conceived of the search strategy. MS, AM, HO-K and CK provided feedback to inform the protocol’s theoretical foundation. AM executed the search. MS, JL, HO-K, SS, JH, CK, DD, MK, KD and AM contributed to the development of the inclusion/ exclusion criteria and to the final manuscript.

**Funding**

This project was funded through an unrestricted Research Start-Up Grants fund from the Office of the Vice President (Research & International) at the University of Manitoba (Mahr).

**Competing interests**

None declared.

**Patient consent for publication**

Not required.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**

Morgan Stirling  http://orcid.org/0000-0002-4286-0688

**REFERENCES**


